Salus Bioceutical extend their Service Agreement

extractX Ltd. Announces Salus Bioceutical (Thailand) Co. Ltd. have signed an Agreement to extend their Service Agreement with an Intent to Buy the Lab in 2025.

Niagara, ON February 25, 2025

extractX Ltd. (“extractX” or the “Company),  is proud to announce Salus Bioceutical (Thailand) Co., Ltd (“Salus”) has signed an Agreement to extend its previous contract into 2025 and intend to Buy the extractX Lab by end of 2025. Salus original agreement was signed on April 6, 2021, which had extension options that Salus decided to execute on.

Wittawin Vidthayanon, Chief Operating Officer, Salus stated “The extractX labs are also cost-effective, boosting our production while saving space and investment costs. The comprehensive support we received for installation, training, and process validation has been invaluable.”

“We have established a good partnership, and we are looking forward to working together for many years to come” stated Albert Iannantuono, Co-CEO of extractX Ltd.

Salus Bioceutical (Thailand) Co., Ltd recently achieved PIC/S approval and is actively working towards EU GMP compliance, which will significantly expand its reach into new markets. With Thailand’s recent tightening of cannabis regulations, Salus is uniquely positioned to grow as one of the country’s few fully compliant, fully integrated companies, focusing exclusively on the non-recreational, medical cannabis market.

About extractX Ltd.

extractX designs, builds, and operates industrial-scale, self-contained mobile extraction laboratories equipped with the most effective and reliable technology. Designed for 24/7 efficiency and unlimited scalability, our labs meet the demands of operations of any size. Built to GPP, GMP, and EU GMP standards, extractX delivers purpose-built mobile extraction solutions—providing biomass cultivators and producers with on-site, on-demand service anywhere in the world.

Forward-Looking Statements

Certain statements contained herein constitute forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Such statements include, without limitation, statements regarding business and financing, business trends and future operating revenues and expenses. Statements regarding the aforementioned are based on several assumptions and are not to be considered fact. Although extractX Ltd. believes that the statements are reasonable, it can give no assurances that such expectation will prove to be correct. Investors are cautioned that any forward-looking statements made by extractX Ltd. contain no guarantee of future performance and that actual results may differ materially from those set forth in the forward-looking statements. For additional information see the reports filed by the company in its securities filings with applicable securities regulators (currently available at www.sedar.com). Unless otherwise required by applicable securities laws, extractX Ltd. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Unless otherwise required by applicable securities laws, extractX Ltd. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information

Albert Iannantuono, Co-CEO
extractX Ltd.
129 Hagar Street, Unit 4 Suite 600, Welland, ON L3B 5V9
905-327-5313